ARTES and BioSun Collaborate on HPV Vaccine

ARTES Biotechnology and BioSun Pharmed will collaborate to develop and manufacture a human papilloma virus (HPV) vaccine in Iran, the companies announced on Nov. 4, 2016. ARTES specializes in cell-line and process development of virus like particle (VLP)-based vaccines and in technology transfer for pharmaceutically relevant production processes. BioSun Pharmed manufactures vaccines and biopharmaceutical products for the domestic Iran and international markets.

“This agreement is the next step in ARTES’ strategy to develop from a service provider for process development to a partner for full pharmaceutical product development,” said Michael Piontek, founder and managing director of ARTES Biotechnology, in the press release. For the first time, ARTES will be responsible for process development of API, formulation, quality control, and supply of preclinical test material. In addition, ARTES will be engaged in the design of the manufacturing site at BioSun and in the selection of third parties for GMP manufacturing.